HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jocelyn Holash Selected Research

Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

1/2009Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade.
12/2008VEGF Trap induces antiglioma effect at different stages of disease.
1/2008Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation.
11/2007VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.
4/2007VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.
10/2005Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
9/2004Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
3/2004TNP-470 promotes initial vascular sprouting in xenograft tumors.
2/2004The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis.
6/2003Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jocelyn Holash Research Topics

Disease

19Neoplasms (Cancer)
01/2018 - 08/2002
3Neoplasm Metastasis (Metastasis)
10/2005 - 06/2003
3Wilms Tumor (Wilm's Tumor)
09/2004 - 08/2002
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2015 - 12/2013
2Carcinogenesis
03/2013 - 06/2003
2Glioblastoma (Glioblastoma Multiforme)
12/2008 - 04/2007
1Leukemia
11/2015
1Hematologic Neoplasms (Hematological Malignancy)
11/2015
1Genomic Instability
01/2015
1Breast Neoplasms (Breast Cancer)
03/2013
1Brain Neoplasms (Brain Tumor)
12/2008
1Glioma (Gliomas)
12/2008
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
08/2008
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
08/2008
1Ascites
10/2005
1Cachexia
10/2005
1Ovarian Neoplasms (Ovarian Cancer)
10/2005
1Residual Neoplasm
06/2003
1Neuroblastoma
08/2002
1Pathologic Neovascularization
08/2002

Drug/Important Bio-Agent (IBA)

12Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2009 - 08/2002
8afliberceptIBA
12/2008 - 08/2002
4Proteins (Proteins, Gene)FDA Link
01/2015 - 02/2004
3Phosphotransferases (Kinase)IBA
11/2015 - 02/2004
3Monoclonal AntibodiesIBA
03/2013 - 08/2002
2Protein Isoforms (Isoforms)IBA
04/2014 - 12/2013
1Sunitinib (Sutent)FDA Link
01/2018
1regorafenibIBA
01/2018
1Immunoconjugates (Immunoconjugate)IBA
01/2018
1Imatinib Mesylate (Gleevec)FDA Link
01/2018
11,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
01/2015
1DNA (Deoxyribonucleic Acid)IBA
01/2015
1proto-oncogene proteins pimIBA
04/2014
1Aromatase InhibitorsIBA
03/2013
1Estrogen ReceptorsIBA
03/2013
1Peptide Hormones (Polypeptide Hormones)IBA
03/2013
1ProlactinIBA
03/2013
1CarcinogensIBA
03/2013
1Prolactin Receptors (Prolactin Receptor)IBA
03/2013
1Letrozole (Femara)FDA LinkGeneric
03/2013
1Bevacizumab (Avastin)FDA Link
01/2009
1Angiopoietin-1IBA
01/2009
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
08/2008
1Interleukin-8 (Interleukin 8)IBA
08/2008
1lucatumumabIBA
08/2008
1CD5 AntigensIBA
08/2008
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2008
1Interleukin-10 (Interleukin 10)IBA
08/2008
1Interleukin-6 (Interleukin 6)IBA
08/2008
1CytokinesIBA
08/2008
1Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA
01/2008
1Messenger RNA (mRNA)IBA
01/2008
1perlecanIBA
01/2008
1Biomarkers (Surrogate Marker)IBA
11/2007
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
04/2007
1LectinsIBA
10/2005
1Fluorescein-5-isothiocyanate (FITC)IBA
10/2005
1Paclitaxel (Taxol)FDA LinkGeneric
10/2005
1Angiogenesis InhibitorsIBA
03/2004
1O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)IBA
03/2004
1tyrosine receptor (receptor, tyrosine)IBA
02/2004
1Oncogene Proteins (Oncogene Protein)IBA
02/2004

Therapy/Procedure

5Therapeutics
04/2014 - 08/2002
1Radiotherapy
04/2007
1Euthanasia (Mercy Killing)
10/2005